Skip to content
Home › 13F recaps › Q3 2026 › EW

Which funds bought or sold EW in Q3 2026?

Edwards Lifesciences Corp. 8 funds bought, 2 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$16M.

Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)

PostLinkedIn
Who bought and who sold EW, by estimated dollars
◀ SoldBought ▶

Top 10 each side. NEW = opened a position, OUT = sold the whole position.

Bought (8)

FundChangeEst. $Now
Arrowstreet
Quant & multi-strategy
Added+79.6%+$390M$880M
Millennium
Quant & multi-strategy
Added+62.8%+$194M$504M
Balyasny
Quant & multi-strategy
Added+192.8%+$76M$115M
Jennison
Growth / crossover
Added+244%+$50M$71M
Adage
Hedge fund
Added+75.7%+$47M$109M
Baillie Gifford
Growth / crossover
Added+44%+$46M$150M
Schonfeld
Quant & multi-strategy
Added+173.8%+$28M$45M
PRIMECAP
Growth / crossover
Added+5.2%+$15M$309M

Sold (2)

FundChangeEst. $Now
AllianceBernstein
Asset manager
Trimmed-12.7%−$95M$653M
Brown Advisory
Asset manager
Trimmed-12.3%−$79M$557M

Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.

Most bought in Q3 2026 → · Most sold →

Weekly digest · free

13F filings and guru moves, in one short email

A Sunday digest of what famous investors said and filed this week, plus an alert when someone changes stance. Free, no spam, unsubscribe anytime.